Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    NEXT STORY
    Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
    PREV STORY
    Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting

    KING OF PRUSSIA, Pa., April 06, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today ...

    author_avatar
    NASDAQ Market News

    NewLink Genetics to Participate in 2017 SunTrust Orphan Drug Day on February 14th

    AMES, Iowa, Feb. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Preclinical CRO Market Report to Grow at a Stellar Pace Reflecting a 8.14% CAGR, is Set to Reach USD 5,234.7 million By 2024-End, Analysis by Market Research Future

    author_avatar
    NASDAQ Market News